生物制剂及小分子靶向药治疗掌跖脓疱病研究进展  

Update of biologics and small molecule targeted drugs for the treatment of palmoplantar pustulosis

作　　者：杨雁南 王俊慧[1] YANG Yannan;WANG Junhui(Department of Dermatology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China)

机构地区：[1]中国中医科学院广安门医院,北京100053

出　　处：《中国麻风皮肤病杂志》2024年第9期669-673,共5页China Journal of Leprosy and Skin Diseases

基　　金：中国中医科学院科技创新工程项目(编号:CI2021A02314)。

摘　　要：掌跖脓疱病(palmoplantar pustulosis,PPP)是一种局限于掌跖部位的慢性复发性皮肤病,目前尚无统一的治疗标准,生物制剂及小分子靶向药物作为新兴药物,目前已开展多项临床试验及病例系列研究,本文就PPP相关生物制剂及小分子靶向药物临床研究进展进行综述,为进一步开展临床治疗和相关药物研发提供参考。Palmoplantar pustulosis(PPP)is a chronic recurrent disease confined to the palmoplantar region,and there is no uniform standard of treatment.Targeted drugs and emerging drugs have been carried out in several clinical trials and case series studies.This paper reviews the progress of clinical research on PPP-related biologics and small molecule targeted drugs to provide a reference for further clinical treatment and related drug development.

关 键 词：生物制剂 小分子靶向药物 掌跖脓疱病 临床试验 病例系列研究 

分 类 号：R758.6[医药卫生—皮肤病学与性病学]